Prelude Therapeutics (PRLD) Corporate presentation summary

Leadership and strategic partnerships

• Leadership team includes experienced executives with backgrounds at major pharma and biotech firms.

• Exclusive option agreement with Incyte provides $35M upfront, $25M equity investment, and up to $875M in milestones and royalties for JAK2V617F program.

Pipeline and clinical development

• Lead asset PRT12396 is a JAK2V617F mutant selective inhibitor in Phase 1 for myeloproliferative neoplasms (MF, PV), with IND cleared in January 2026 and enrollment underway.

• PRT13722, a highly selective oral KAT6A degrader, is on track for IND filing mid-2026 targeting ER+ breast cancer.

• mCALR DAC program targets mutated calreticulin in MPNs, showing >100x potency over current clinical antibodies.

Scientific innovation and differentiation

• PRT12396 binds the JAK2 JH2 deep pocket, offering >200x selectivity over JAK1/TYK2 and a 10x therapeutic window in preclinical models.

• PRT13722 demonstrates absolute selectivity for KAT6A over KAT6B, robust monotherapy and combination efficacy, and lower bone marrow toxicity compared to dual inhibitors.

• mCALR-targeted DACs deliver degrader payloads to disease-initiating clones, with robust in vitro and in vivo activity and ~100x improved potency in CALR mutant cells.